Erika L Spaeth (Erika Spaeth, Erika Spaeth Tuff)

Publication Activity (10 Years)

Years Active: 2016-2023
Publications (10 Years): 14

Top Topics

Dendritic Cells

Breast Cancer Risk

Top Venues

Breast cancer research and treatment

The Journal of experimental medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Erika L Spaeth, Gillian S Dite, John L Hopper, Richard Allman
Validation of an abridged breast cancer risk prediction model for the general population. Cancer prevention research (Philadelphia, Pa.) (2023)
Richard Allman, Yi Mu, Gillian S Dite, Erika L Spaeth, John L Hopper, Bernard A Rosner
Validation of a breast cancer risk prediction model based on the key risk factors: family history, mammographic density and polygenic risk. Breast cancer research and treatment (2023)
Richard Allman, Yi Mu, Gillian S Dite, Erika L Spaeth, John L Hopper, Bernard A Rosner
Validation of a breast cancer risk prediction model based on the key risk factors: family history, mammographic density and polygenic risk. Breast cancer research and treatment 198 (2) (2023)
Richard Allman, Yi Mu, Gillian S Dite, Erika L Spaeth, John L Hopper, Bernard A Rosner
Validation of a breast cancer risk prediction model based on the key risk factors: family history, mammographic density and polygenic risk. Breast cancer research and treatment 198 (2) (2023)
Richard Allman, Yi Mu, Gillian S Dite, Erika L Spaeth, John L Hopper, Bernard A Rosner
Validation of a breast cancer risk prediction model based on the key risk factors: family history, mammographic density and polygenic risk. Breast cancer research and treatment (2023)
Richard Allman, Yi Mu, Gillian S Dite, Erika L Spaeth, John L Hopper, Bernard A Rosner
Validation of a breast cancer risk prediction model based on the key risk factors: family history, mammographic density and polygenic risk. Breast cancer research and treatment 198 (2) (2023)
Gillian S Dite, Erika L Spaeth, Nicholas M Murphy, Richard Allman
Development and validation of a simple prostate cancer risk prediction model based on age, family history, and polygenic risk. The Prostate (2023)
Richard Allman, Yi Mu, Gillian S Dite, Erika L Spaeth, John L Hopper, Bernard A Rosner
Validation of a breast cancer risk prediction model based on the key risk factors: family history, mammographic density and polygenic risk. Breast cancer research and treatment 198 (2) (2023)
Richard Allman, Yi Mu, Gillian S Dite, Erika L Spaeth, John L Hopper, Bernard A Rosner
Validation of a breast cancer risk prediction model based on the key risk factors: family history, mammographic density and polygenic risk. Breast cancer research and treatment 198 (2) (2023)
Richard Allman, Yi Mu, Gillian S Dite, Erika L Spaeth, John L Hopper, Bernard A Rosner
Validation of a breast cancer risk prediction model based on the key risk factors: family history, mammographic density and polygenic risk. Breast cancer research and treatment 198 (2) (2023)
Gillian S Dite, Nicholas M Murphy, Erika L Spaeth, Richard Allman, null null
Validation of a clinical and genetic model for predicting severe COVID-19. Epidemiology and infection (2022)
Richard Allman, Erika L Spaeth, John Lai, Susan J Gross, John L Hopper
A streamlined model for use in clinical breast cancer risk assessment maintains predictive power and is further improved with inclusion of a polygenic risk score. PloS one 16 (1) (2021)
Athena S Davenport, Richard Allman, Gillian S Dite, John L Hopper, Erika L Spaeth, Stewart Macleod, Susan Kadlubar, Michael Preston, Ronda Henry-Tillman
Validation of a genetic risk score for Arkansas women of color. PloS one 13 (10) (2018)
Srdan Verstovsek, Taghi Manshouri, Darrell Pilling, Carlos E Bueso-Ramos, Kate J Newberry, Sanja Prijic, Liza Knez, Ksenija Bozinovic, David M Harris, Erika L Spaeth, Sean M Post, Asha S Multani, Raajit K Rampal, Jihae Ahn, Ross L Levine, Chad J Creighton, Hagop M Kantarjian, Zeev Estrov
Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. The Journal of experimental medicine 213 (9) (2016)